Clinical Trial Update: Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

This document provides an extension study update on the efficacy and safety of oral SCIO-469 in relapsed, refractory multiple myeloma (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SCIO-469

Snippet

Sponsor: Scios, Inc. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED